LEO LABORATORIES LIMITED

🇮🇪Ireland

Country: 🇮🇪Ireland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

Phase 2

Terminated

Conditions: Discoid Lupus Erythematosus

Interventions: Drug: Delgocitinib cream vehicle
Drug: Delgocitinib cream

First Posted Date: 2019-05-22

Last Posted Date: 2021-06-28

Lead Sponsor: LEO Pharma

Target Recruit Count: 27

Registration Number: NCT03958955

Locations: 🇩🇰
LEO Pharma Investigational site, Hellerup, Denmark
🇩🇪
LEO Pharma Investigational Site, Oldenburg, Germany

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.

Phase 1

Completed

Conditions: Psoriasis Vulgaris

Interventions: Drug: Microarray patch B
Drug: Placebo
Drug: Daivobet
Drug: Microarray patch A

First Posted Date: 2019-04-02

Last Posted Date: 2020-09-11

Lead Sponsor: LEO Pharma

Target Recruit Count: 15

Registration Number: NCT03898583

Locations: 🇩🇪
LEO Pharma investigational site, Hamburg, Germany

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: delgocitinib

First Posted Date: 2019-02-01

Last Posted Date: 2024-11-07

Lead Sponsor: LEO Pharma

Target Recruit Count: 46

Registration Number: NCT03826901

Locations: 🇨🇦
LEO Pharma investigational site, Montréal, Quebec, Canada

A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LEO 32731 modified release tablet
Drug: LEO 32731
Drug: LEO 32731 blend, hard capsule
Drug: LEO 32731 soft capsule
Other: Placebo
Drug: LEO 32731 API, hard capsule
Drug: LEO 32731 gastro-resistant capsule

First Posted Date: 2019-01-23

Last Posted Date: 2019-07-01

Lead Sponsor: LEO Pharma

Target Recruit Count: 66

Registration Number: NCT03812198

Locations: 🇬🇧
LEO Pharma Investigational Site, Leeds, United Kingdom

Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris

Phase 3

Completed

Conditions: Psoriasis Vulgaris

Interventions: Drug: LEO 90100 foam
Drug: Dovobet® ointment

First Posted Date: 2019-01-16

Last Posted Date: 2020-12-16

Lead Sponsor: LEO Pharma

Target Recruit Count: 182

Registration Number: NCT03806790

Locations: 🇯🇵
Leo Pharma Investigational Site, Setagaya, Tokyo, Japan

A Study to Learn More About the Relationship Between the Development of a Gap in the Upper Lip (Cleft Lip) or in the Roof of the Mouth (Cleft Palate) in Newborns and the Use of Glucocorticoids by the Mother During Pregnancy: a Meta-analysis

Completed

Conditions: Relationship Between the Exposure of Glucocorticoids During Pregnancy and Orofacial Cleft Development

Interventions: Drug: Diflucortolone valerate (BAY866146)

First Posted Date: 2018-12-28

Last Posted Date: 2020-04-01

Lead Sponsor: LEO Pharma

Target Recruit Count: 99999

Registration Number: NCT03788863

Locations: 🇩🇪
Many locations, Multiple Locations, Germany

Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Other: Placebo
Drug: Tralokinumab

First Posted Date: 2018-12-03

Last Posted Date: 2024-08-01

Lead Sponsor: LEO Pharma

Target Recruit Count: 277

Registration Number: NCT03761537

Locations: 🇬🇧
Leo Pharma Investigationel Site, Wakefield, United Kingdom

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Delgocitinib cream
Drug: Delgocitinib cream vehicle

First Posted Date: 2018-10-31

Last Posted Date: 2024-08-22

Lead Sponsor: LEO Pharma

Target Recruit Count: 251

Registration Number: NCT03725722

Locations: 🇦🇺
Leo Pharma Investigational Site 1, Kogarah, Australia
🇨🇦
Leo Pharma Investigational Site, Toronto, Ontario, Canada

Investigation of Flare and Remission in Subjects With Atopic Dermatitis

Phase 4

Withdrawn

Conditions: Atopic Dermatitis

Interventions: Drug: Cyclosporine A

First Posted Date: 2018-10-17

Last Posted Date: 2024-11-07

Lead Sponsor: LEO Pharma

Registration Number: NCT03710044

Locations: 🇳🇱
Investigational site, Rotterdam, Netherlands

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

Phase 2

Completed

Conditions: Chronic Hand Eczema

Interventions: Drug: Delgocitinib cream
Drug: Delgocitinib cream vehicle

First Posted Date: 2018-09-25

Last Posted Date: 2024-08-22

Lead Sponsor: LEO Pharma

Target Recruit Count: 258

Registration Number: NCT03683719

Locations: 🇩🇰
LEO Pharma Investigational Site, Herlev, Denmark
🇩🇪
Leo Pharma Investigational Site, Wuppertal, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy